Matches in Wikidata for { <http://www.wikidata.org/entity/Q92576222> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q92576222 description "article scientifique publié en 2019" @default.
- Q92576222 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92576222 description "scientific article published on 06 June 2019" @default.
- Q92576222 description "wetenschappelijk artikel" @default.
- Q92576222 description "наукова стаття, опублікована 6 червня 2019" @default.
- Q92576222 name "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 name "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 type Item @default.
- Q92576222 label "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 label "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 prefLabel "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 prefLabel "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 P1433 Q92576222-E3AD7884-79B2-45C9-A626-48DCFD641734 @default.
- Q92576222 P1476 Q92576222-9ECDB814-DEEA-4204-A08E-AD2FB99D0CD6 @default.
- Q92576222 P2093 Q92576222-8108467C-A855-47D8-8ED0-27E4427BE7B4 @default.
- Q92576222 P2093 Q92576222-92D279DA-C529-4E5B-B446-8FCD4C819B23 @default.
- Q92576222 P304 Q92576222-C0AFEFF4-0F94-4212-BDB6-88C161454ADD @default.
- Q92576222 P31 Q92576222-486D03AD-EBFE-4348-892E-BA83760F6984 @default.
- Q92576222 P356 Q92576222-FEEF16F5-7412-497C-AFCD-12DC763E4E8F @default.
- Q92576222 P433 Q92576222-CBC77B03-F491-45E2-9736-93B9D3E765DB @default.
- Q92576222 P478 Q92576222-ACBF0BFC-7C61-4123-A0B6-9BFC44BAF5D4 @default.
- Q92576222 P50 Q92576222-0BB8B508-D50B-4F33-8CF6-CF64D1928A62 @default.
- Q92576222 P50 Q92576222-3039AA5D-A494-4BE9-B076-35E5227416BD @default.
- Q92576222 P50 Q92576222-D85E87AB-9C42-4F5B-AE7E-059AB9247648 @default.
- Q92576222 P50 Q92576222-E716E3CE-2456-4215-AF1E-BCCAD832E465 @default.
- Q92576222 P577 Q92576222-AF674277-AC35-4D27-B92B-FC4DAFD5893C @default.
- Q92576222 P698 Q92576222-48768C2E-D6C0-48B0-99B4-D707EB407D9D @default.
- Q92576222 P921 Q92576222-4679F7F2-54B5-4956-BA1A-78E8057E37F3 @default.
- Q92576222 P921 Q92576222-4891DF26-E1D8-4D8E-AD2B-FFB8CEDBF681 @default.
- Q92576222 P921 Q92576222-9EE99971-786E-48DC-9B4D-3FE998C6E5CC @default.
- Q92576222 P356 S10549-019-05309-6 @default.
- Q92576222 P698 31172405 @default.
- Q92576222 P1433 Q326085 @default.
- Q92576222 P1476 "Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease" @default.
- Q92576222 P2093 "John W Park" @default.
- Q92576222 P2093 "Michael Assefa" @default.
- Q92576222 P304 "401-408" @default.
- Q92576222 P31 Q13442814 @default.
- Q92576222 P356 "10.1007/S10549-019-05309-6" @default.
- Q92576222 P433 "2" @default.
- Q92576222 P478 "177" @default.
- Q92576222 P50 Q114417827 @default.
- Q92576222 P50 Q117271106 @default.
- Q92576222 P50 Q55975497 @default.
- Q92576222 P50 Q92576217 @default.
- Q92576222 P577 "2019-06-06T00:00:00Z" @default.
- Q92576222 P698 "31172405" @default.
- Q92576222 P921 Q412197 @default.
- Q92576222 P921 Q425088 @default.
- Q92576222 P921 Q5062122 @default.